Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
eNq1mF1v2jAUhu/5FVHuiQmjXZkC1cbaDanVGC3atBtkkkNx5tqpP/jYr59D6EYnRx0GX8Z2Xh/7vH585ORy/UiDJQhJOOuFcdQKA2Apzwh76IWT++vmRXjZbyQ5XuK9YWZc1G6HQUqxlL2w7I1mgJmMvt/efATzP4iw3wgSPsshVS/GaUVo9BnLxS0uyjFBsuQkCx5BLXjWCwuttq1BIpUwUfRXXPyUBU4hQbuW/d582tlvT1Ap9h+qWoK4wezBKgrMSTPVQgBTA6zggYtNTbxvnLSJHIPkWqQwwmoxEnxJMsisU8wxleA0yXyV3YFYUlDlJFZxlKeP0kkc53g9hqehPej3pneg1qrZasZv47O41e22W52OW3LF3lbZs2AWgdJpfN656Ha7CBjKJcoxJVyirT9z6ZilERcKU0/5IXLw0mKe5hHw9KoPMiILijdmpwrXrcICm24QBgT+FlKu4F4YNFGzZ//oM00pOjDqyQ4cniIuuTTgmqkaflyPXTdiwJmCdX1G3ZCn1jsvEpCnk/3FmR33Iz2jJHWFm8GPBqkm42E92/xg4QOWMBH+uPCNsIyv5Ol5s59fT9EXW2RaRQuRxdN29+I8PjtzPk4/jJlqbp0rLXgByJCIyGMAM2RzfixajD/tUs/u9GDMbRXEU0yhpg6aOvLGOPK5bPPmeX/nqeqwin66unc1ylcNYnO3/bRKk6z3J8VuMPZBeGPL2sAPN3l11r1UyFrYGbJQqpDvEFqtVtECy6bEZpeiufBI+72r1l+l7uU+r+qbipieQp9VV+FhuXI9c6/d+MdWsbv/d9WydQ4lNByRiwrP3iA6vDo9l/+WsN7CHr3giL9ptuUmVoQzX8WPnlkVj7sJTF7ZtTCA+DKfk5qXk1pfJqh6tek3ElS+2PQbvwFnxfOe
LARQujzePDBQPJW1